Soluble membrane attack complex in the blood and cerebrospinal fluid of HIV-infected individuals, relationship to HIV RNA, and comparison with HIV negatives

• Type of Material: Article
• Authors: Albert Anderson, Emory University; Theresa N. Schein, University of Alabama Birmingham; Aley Kalapila, Emory University; Lillin Lai, Emory University; Drenna Waldrop-Valverde, Emory University; Raeanne C. Moore, University of California San Diego; Donald Franklin, University of California San Diego; Scott L. Letendre, University of California San Diego; Scott R. Barnum, University of Alabama Birmingham
• Language: English
• Date: 2017-10-15
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2017 Elsevier B.V.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.jneuroim.2017.07.014
• Title of Journal or Parent Work: Journal of Neuroimmunology
• ISSN: 0165-5728
• Volume: 311
• Start Page: 35
• End Page: 39
• Grant/Funding Information: Emory Medical Care Foundation; NIH K23MH095679; NIH P30 AI050409 (Emory Center for AIDS Research); Impact Fund of Children’s of Alabama
• Keywords: Neurocognitive disorder; Human immunodeficiency virus; Membrane attack complex; Immunology; Acquired immunodeficiency syndrome; Science & Technology; Neurosciences & Neurology; CELLS; BRAIN; SYSTEM; AGE; Complement; ANTIRETROVIRAL THERAPY; IMMUNE ACTIVATION; Life Sciences & Biomedicine; MARKERS; NEUROCOGNITIVE DISORDERS; Neurosciences
• Research Categories: Health Sciences, Immunology; Psychology, Cognitive; Biology, Neuroscience

Abstract

The soluble membrane attack complex (sMAC) represents the terminal product of the complement cascade. We enrolled 47 HIV + adults (12 of whom underwent a second visit at least 24 weeks after starting therapy) as well as 11 HIV negative controls. At baseline, cerebrospinal fluid (CSF) sMAC was detectable in 27.7% of HIV + individuals. CSF sMAC correlated with CSF HIV RNA levels and was more likely to be detectable in HIV + individuals on cART compared to HIV negative controls. In HIV + participants, there were negative association trends between sMAC and neurocognitive performance but these did not reach statistical significance.